Last reviewed · How we verify
ALX1-11
At a glance
| Generic name | ALX1-11 |
|---|---|
| Also known as | PREOS |
| Sponsor | Shire |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Paresthesia
- Hypocalcemia
- Headache
- Hypercalcemia
- Nausea
- Hypoesthesia
- Diarrhea
- Vomiting
- Arthralgia
- Hypercalciuria
- Pain in extremity
- Upper respiratory tract infection
Key clinical trials
- Calcium Supplementation in Postmenopausal Women (PHASE3)
- Open Label Extension Study of PREOS (PHASE3)
- Open Label Extension (PHASE3)
- A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis (PHASE2)
- TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |